Track topics on Twitter Track topics that are important to you
One Great Valley Parkway, Suite 2
United States of America
Neuronetics Inc. (neurostimulation device to treat psychiatric and neurological disorders)
An initial public offering of 5 million shares has been priced by Malvern, Pa.-based Neuronetics at $14 to $16 each in hopes -More-
An initial public offering was filed with the SEC by Malvern, Pa.-based Neuronetics in hopes of raising up to $86 million. -More-
An initial public offering of 5.5 million shares has been priced by Neuronetics at $17 each in hopes of raising $94 million. -More-
Neuronetics Inc. (neurostimulation device to treat psychiatric and neurological disorders) netted $100mm in its initial public offering of 6.325mm shares (including the overallotment) at $17.00. The c...
The purpose of this study is to determine if the use of Transcranial Magnetic Stimulation (TMS) provides rapid reduction and sustained attenuation of suicidal crisis. TMS is a treatment fo...
The objective of this investigation is to examine the safety and feasibility of a series rTMS treatments (10 Hz; Left Dorsolateral Prefrontal Cortex), with a Neuronetics Model 2100 CRS Rep...
The goal of this proposal is to investigate whether a standard rTMS protocol for depression, including multiple sessions applied to left dorsolateral prefrontal cortex (DLPFC) results in r...
We have published hundreds of Neuronetics news stories on BioPortfolio along with dozens of Neuronetics Clinical Trials and PubMed Articles about Neuronetics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neuronetics Companies in our database. You can also find out about relevant Neuronetics Drugs and Medications on this site too.
Psychiatry is the study of mental disorders and their diagnosis, management and prevention. Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...